Edition:
United Kingdom

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

9.93USD
14 Dec 2017
Change (% chg)

$1.02 (+11.45%)
Prev Close
$8.91
Open
$8.91
Day's High
$10.39
Day's Low
$8.90
Volume
134,647
Avg. Vol
66,543
52-wk High
$21.30
52-wk Low
$3.13

Summary

Name Age Since Current Position

Nassim Usman

51 2015 President, Chief Executive Officer, Director

Fletcher Payne

2015 Chief Financial Officer

Andrew Hetherington

2015 Vice President - Manufacturing Operations

Arwa Shurrab

2017 Vice President - Regulatory Affairs

Jeffrey Landau

2016 Vice President - Business Development

Howard Levy

2016 Chief Medical Officer

Jamie Siegel

2017 Head - Clinical Development

Errol De Souza

63 2015 Director

Stephen Hill

59 2015 Director

Jeffrey Himawan

52 2015 Director

Andrea Hunt

2017 Director

Augustine Lawlor

61 2015 Director

John Richard

57 2015 Director

Harold Selick

62 2015 Director

Biographies

Name Description

Nassim Usman

Dr. Nassim Usman, Ph.D. is President, Chief Executive Officer, Director of the Company. Dr. Usman has served as Chief Executive Officer and a member of the board of directors of Catalyst since February 2006 and as President since May 2015. Dr. Usman joined Catalyst from Morgenthaler Ventures, where he is currently a venture partner. Prior to joining Morgenthaler in 2005, he was senior vice president and chief operating officer at Sirna Therapeutics Inc., which was subsequently acquired by Merck, from 2004 to 2005, and held various R&D positions at both Sirna and Ribozyme Pharmaceuticals, including vice president of R&D and chief science officer, from 1992 to 2004. During his industrial career, Dr. Usman has overseen the entry of several drugs into clinical development, completion of multiple licensing deals with pharmaceutical and biotechnology companies and raise of capital in both private and public financings. Prior to moving into the private sector in 1992, Dr. Usman was an NIH Fogarty and NSERC Postdoctoral Fellow and Scientist in the Departments of Biology and Chemistry at the Massachusetts Institute of Technology from 1987 to 1992. He has authored more than 70 scientific articles and is the named inventor in 130 issued patents and patent applications. Dr. Usman serves on the boards of directors of Mosaic Biosciences and Principia Biopharma, is a past director of Osprey Pharmaceuticals, Archemix Corporation and Atugen AG (now Silence Therapeutics) and served on the science advisory boards of RXi Pharmaceuticals and Noxxon Pharma AG. He received his B.Sc. (Honours) and Ph.D. in Organic Chemistry from McGill University. In his doctoral dissertation, he developed a method for the solid-phase synthesis of RNA that is widely used in science and in a marketed RNA product (Macugen™).

Fletcher Payne

Mr. Fletcher Payne is Chief Financial Officer of the Company., effective September 30, 2015. Mr. Payne has been Catalyst’s Chief Financial Officer since January 2015. Mr. Payne joined Catalyst in a consulting capacity through Danforth Advisors LLC, where he worked as a consultant, until April 2015, when he became a Catalyst employee. He has been a consulting chief financial officer of CFP Advisory since November 2011, and from September 2008 to November 2011, Mr. Payne served as chief financial officer of Pathwork Diagnostics. Mr. Payne has also served in senior financial positions at CytomX Therapeutics, Plexxikon Inc., Rinat Neuroscience Corporation, Dynavax Technologies Corporation, Cell Genesys, Abgenix, Sun Micro Systems, and IBM. Mr. Payne has over 20 years of experience helping life science companies achieve their business goals. His life science experience includes successful start-ups, initial public offerings, mergers, spin-outs, financings, business collaborations and working with R&D teams whose efforts have led to four products receiving FDA clearance. Mr. Payne graduated with a B.S. in Finance from the Haas School of Business, University of California, Berkeley.

Andrew Hetherington

Mr. Andrew Hetherington is Vice President - Manufacturing Operations of Catalyst Biosciences, Inc. Mr. Hetherington brings to Catalyst Biosciences more than two decades of experience in global commercial and clinical manufacturing, technology transfer and product development. Mr. Hetherington previously served as the Head of Immuno Manufacturing at the Diagnostics division of Novartis, where he worked from April 2010 until August 2015 and was responsible for providing recombinant and finished product for Novartis' $400 million blood testing business. Prior to Novartis, from 1998 to 2010, Mr. Hetherington held various key Manufacturing positions at Bayer Healthcare's Biotechnology Division, with the most recent being the Head of New Products and Contract Manufacturing where he was responsible for manufacturing Bayer's commercial recombinant Factor VIII and clinical stage replacements to supply the company's global $1 billion annual business. At Bayer, Mr. Hetherington also held the positions of Director of Manufacturing for the Purification and Plasma group as well as Senior Production Manager of Fermentation, Purification and Plasma. Prior to Bayer, Mr. Hetherington was a Production Manager of Solid Dose Manufacturing and Packaging at Glaxo Wellcome's Pharmaceutical Division.

Arwa Shurrab

Ms. Arwa Shurrab is Vice President - Regulatory Affairs of the Company. Ms. Shurrab brings to Catalyst nearly 25 years of regulatory affairs experience in the hematology field. She has worked extensively leading regulatory and chemistry, manufacturing and controls (CMC) activities. Before joining Catalyst, Arwa was the director of regulatory affairs at Shire, where she served as a director leading the Hematology CMC team in the development of strategic plans and worldwide regulatory submissions. Prior to Shire, she spent over 20 years at Baxter/Baxalta leading regulatory activities for hemophilia products, including but not limited to major BLA approvals and expansion to more than 70 countries. Earlier in her career, Arwa held various positions in quality control and quality assurance. Arwa holds a bachelor of science in chemistry with a minor in biology from The American University in Cairo.

Jeffrey Landau

Mr. Jeffrey Landau is Vice President - Business Development of the Company. Mr. Landau previously served as Director of Corporate Development and Global Strategic Marketing at Threshold Pharmaceuticals since 2012 where he co-led various in-licensing and co-promotion deals. Prior to Threshold, Mr. Landau held increasingly senior global product strategy and new product planning positions at Onyx Pharmaceuticals, where he contributed significantly to global commercial strategy and development related to sorafenib, carfilzomib and regorafenib, all successful oncology products. Earlier in his career, he held various sales positions at Jazz Pharmaceuticals, Orphan Medical and Eli Lilly. Mr. Landau holds a B.S., Biotechnology/Biochemistry In Honors from the Virginia Polytechnic Institute and State University, and an M.B.A. from Stanford University Graduate School of Business.

Howard Levy

Dr. Howard Levy, M.B.B.Ch., Ph.D., M.M.M., is Chief Medical Officer of the Company. Dr. Levy has over 25 years of experience in the pharmaceutical industry. Since 2010, as a CMO or Consultant, he has advised various public and private biotechnology companies on clinical and drug development strategy and execution. In addition, Dr. Levy was the Senior Global Medical Program Director at CSL Bering in 2013, and he was the Senior Vice President and Chief Medical Officer at Inspiration Biopharmaceuticals, a company solely focused on innovation in hemophilia, in 2012. From 2008 to 2011, he served as Chief Medical Officer at Sangart, Inc., which was developing pegylated hemoglobin as an oxygen therapeutic agent and a treatment for sickle cell crisis. Prior to Sangart, from 2006 to 2008, Dr. Levy was Associate Vice President, Clinical Research, Medical and Regulatory Affairs, at Novo Nordisk and was responsible for a number of clinical research programs, including recombinant factor VIIa. Earlier in his career, Dr. Levy was Clinical Research Physician and Medical Director, Acute Care in the U.S. Medical Division of Eli Lilly and Company supporting post-marketing clinical trials and medical affairs for recombinant Activated Protein C (Xigris) in severe sepsis and antiplatelet agents ReoPro and prasugrel. He was also Chief of Critical Care Medicine at the University of New Mexico in Albuquerque for 11 years. Dr. Levy holds M.B.B.Ch and Ph.D. degrees from University of the Witwatersrand in Johannesburg, South Africa and a M.M.M. from Carnegie Mellon University’s H. John Heinz III College.

Jamie Siegel

Ms. Jamie Siegel is Head - Clinical Development of the Company. Ms. Ellen Siegel, M.D., brings to Catalyst over 30 years of clinical, clinical laboratory, and program development experience in the hematology field, particularly in hemophilia, with the last ten years in government and industry settings. Jamie was director of the Hemophilia and Thrombosis Center, Cardeza Foundation Special Hemostasis Laboratory, and associate professor of medicine at Thomas Jefferson University. She was co-director of the Medical Advisory Board for the Hemophilia Federation of America and has received numerous humanitarian awards from hemophilia patient advocacy groups. Before joining Catalyst, Jamie held a number of high-level positions, including medical director at Novo Nordisk and global clinical leader at Bayer where she worked on two major hemophilia programs, and was Chief, Thrombosis and Hemostasis branch at the National Institutes of Health. She has overseen numerous clinical trials and has authored over 35 hematology publications, including almost 20 peer-reviewed papers, seven peer-reviewed review articles, and seven book chapters. Jamie received her medical degree from the Medical College of Pennsylvania and holds a bachelor of arts from Lehigh University.

Errol De Souza

Dr. Errol B. De Souza, Ph.D. is Director of the company. He has been the president and chief executive officer of Biodel, a specialty pharmaceutical company, since March 2010. From April 2009 to March 2010, Dr. De Souza was a pharmaceutical and biotechnology consultant. From April 2003 to March 2009, he served as president and chief executive officer of Archemix Corporation, a privately held biopharmaceutical company. Dr. De Souza has served as president and chief executive officer of Synaptic Pharmaceutical Corp. until its sale to H. Lundbeck A/S. Dr. De Souza has served in key leadership roles such as senior vice president and head of global lead generation for Hoechst Marion Roussel and senior vice president and U.S. head of drug innovation and approval following that company’s merger with Rhône-Poulenc to form Aventis and co-founder and executive vice president of research and development at Neurocrine Biosciences, Inc. Dr. De Souza was a member of the board of directors of Targacept since January 2004 and became a member of the board of directors of Catalyst in August 2015. Dr. De Souza currently serves as a member of the board of directors of each of the publicly traded companies Biodel Inc. and Bionomics Ltd. In the past, Dr. De Souza has also served on boards of IDEXX Laboratories, Inc. and Palatin Technologies, Inc. Dr. De Souza received his B.A. in physiology and his Ph.D. in neuroendocrinology from the University of Toronto and he received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine.

Stephen Hill

Dr. Stephen Anthony Hill, M.D. Director of the company., He was the president and chief executive officer of Targacept since December 2012. From May 2012 to November 2012, Dr. Hill served as president and chief executive officer of QUE Oncology, a start-up biotechnology company, and, from March 2011 to December 2011, he served as president and chief executive officer of 21st Century Biodefense, Inc., a biodefense company. From April 2008 until its acquisition in December 2010, he served as president and chief executive officer of Solvay Pharmaceuticals, Inc., a pharmaceutical company. Prior to Solvay, he was the president, chief executive officer and director of ArQule, Inc., a pharmaceutical company, from April 1999 to March 2008. Dr. Hill has extensive experience across a range of senior management positions with both pharmaceutical and biotechnology companies. Prior to Solvay and ArQule, Dr. Hill held several leadership positions with F. Hoffmann-La Roche Ltd., including Global Head of Clinical Development, and served for seven years with the National Health Service in the United Kingdom in General and Orthopedic Surgery. Dr. Hill was a member of the board of directors of Targacept since December 2012 and became a member of the board of directors of Catalyst in August 2015. He is also a member of the board of directors of Cellectar Biosciences, Inc. (formerly Novelos Therapeutics, Inc.) and Lipocine, Inc. Dr. Hill is a Fellow of the Royal College of Surgeons of England and holds degrees in medicine and surgery from St. Catherine’s College at Oxford University.

Jeffrey Himawan

Mr. Jeffrey Himawan is Director of the company. He is currently a managing director at Essex Woodlands Health Ventures, a healthcare focused venture capital firm, where he previously served as a venture partner from 2001 to 2004 and as an adjunct partner from 1999 to 2001. He has over 20 years of experience as a scientist, entrepreneur and venture capitalist. Dr. Himawan was a co-founder and managing director of Seed-One Ventures, LLC, a venture capital firm that specializes in the initial formation, financing and early operational development of technology-based companies, from 1996 to 2001. From 1983 to 1996, Dr. Himawan was a scientist in both academic and industrial settings. Dr. Himawan has been a member of the board of directors of Catalyst since December 2008. He currently serves as a director of MediciNova, Horizon Pharma, Light Sciences Oncology, OMT Therapeutics and Symphogen. He has previously served as a director of Iomai and Complete Genomics. Dr. Himawan received his B.S. from Massachusetts Institute of Technology and his Ph.D. from Harvard University.

Andrea Hunt

Ms. Andrea Hunt is Director of the Company. Ms. Andrea Hunt was most recently vice president, New Product Gene Therapy, Neuroscience, Oncology & Ophthalmology at Shire, Plc., where she was developing and integrating strategies for Shire's gene therapy platform. Ms. Hunt came to Shire through its acquisition of Baxalta, where she led the Global Blood Disorders Franchise within the Hematology Division. Prior to Baxalta, Ms. Hunt held several positions of increasing responsibility at Baxter Healthcare leading to her appointment as project leader to Baxter Healthcare's R&D program, BAX855, now Adynovate™. Ms. Hunt served on the board for the Alliance for Regenerative Medicine and is an advisor to the Angiogenesis Foundation. Ms. Hunt earned her MBA in marketing from the University of Michigan and her B.S. in hospital dietetics and B.A. in foods and nutrition from the University of Illinois.

Augustine Lawlor

Mr. Augustine J. Lawlor is Director of the company. He has been a managing director of HealthCare Ventures since 2000. From 1997 to 2000, he served as chief operating officer of LeukoSite, Inc., a HealthCare Ventures III, IV and V company. Prior to joining LeukoSite, Mr. Lawlor was chief financial officer and vice president of corporate development for Alpha-Beta Technology. He has held similar positions at both BioSurface Technology and Armstrong Pharmaceuticals. Mr. Lawlor was previously a management consultant with KPMG Peat Marwick. Mr. Lawlor has been a member of the board of directors of Catalyst since February 2006. He is currently a director of Cardiovascular Systems, Globe Immune, Promedior, Inc., Mosaic Biosciences, Inc., Tensha Therapeutics, Inc., HealthCare Pharmaceuticals, Inc., Cleveland HeartLab, LLC, GITR, Inc., Anexon, Inc. and the Slater Center for Biomedical Technology, a technology commercialization center providing support services for development of therapeutics. Mr. Lawlor has previously served as a director of uman Genome Sciences, which was acquired by GlaxoSmithKline and Replidyne, Inc. Mr. Lawlor received his Master’s in Public and Private Management from Yale University.

John Richard

Mr. John P. Richard is Director of the company. He is an operating partner at the life science investment firm Phase4 Partners (formerly Nomura Phase4 Ventures), and has served as a non-executive director for Phase4 since March 2011 and as a venture partner since 2008. Since 2005 he has also been a managing director of Georgia Venture Partners, a seed venture capital firm that focuses on the biotechnology industry. In addition, Mr. Richard currently serves and from time to time during at least the past five years has served as a consultant to Phase4 Partners (or its predecessor) and certain of its portfolio companies, and to portfolio companies of Georgia Venture Partners. Mr. Richard was a member of the board of directors of Targacept since November 2002, and served as Chairman since January 2014. Mr. Richard became a member of the board of directors of Catalyst in August 2015. Mr. Richard is a director of Biota Pharmaceuticals, Inc. Mr. Richard served as a member of the board of directors of the formerly publicly-traded company Altus Pharmaceuticals Inc. Mr. Richard received his M.B.A. from the Harvard Business School and a B.S. from Stanford University.

Harold Selick

Dr. Harold E. Selick is Director of the company. He joined Threshold as Chief Executive Officer in June 2002. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for treating kidney transplant rejection. Dr. Selick has been a member of the board of directors of Catalyst since 2003 and became Chairman of the Board of Directors in 2006. Dr. Selick also currently serves as Lead Director of Protein Design Labs, Inc. as well as the Chairman of the Board of Directors of Protagonist Therapeutics, Inc. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.